BAIYUNSHAN PH (00874) has announced its interim results for 2026, with revenue reaching approximately RMB 42.091 billion, a modest increase of 0.61% year-on-year. Net profit attributable to shareholders of the company stood at about RMB 2.096 billion, reflecting a decline of 16.7% compared to the same period last year. Basic earnings per share were RMB 1.289, with an interim cash dividend of RMB 0.30 per share (pre-tax).

During the reporting period, sales revenue for key products such as Angong Niuhuang Wan, amoxicillin series, cefixime series, Xiao'er Qixing Cha, and Kunxian capsules achieved rapid growth year-on-year. The group also actively advanced its participation in national and regional centralized procurement tenders, while strategically positioning itself for inclusion in the National Essential Medicines List.

In this reporting period, 24 products, including cefuroxime sodium for injection, clindamycin phosphate injection, memantine hydrochloride tablets, and amoxicillin granules, were successfully selected in the national centralized procurement program for the 1st to 8th batches of continuous supply. Following the reporting period, 19 specifications, such as Xiao Chai Hu granules, were newly included in the National Essential Medicines List (2026 Edition). Additionally, the group continued to strengthen brand development by establishing a proprietary brand matrix to amplify the market influence of local brands. Simultaneously, efforts were intensified in merchant recruitment and expansion, with hundreds of high-quality products opening cooperation channels at promotional conferences to further broaden its sales network.

Looking ahead, the group projects total capital expenditure of approximately RMB 2.152 billion for 2026, of which RMB 536 million had been spent in the first half of 2026 (compared to RMB 649 million in the first half of 2025). These investments are primarily allocated to production base construction, equipment upgrades, and information system development.